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introduction: C-reactive protein circulates as a pentameric protein (pCRP). pCRP is 
a well-established diagnostic marker as plasma levels rise in response to tissue injury 
and inflammation. We recently described pro-inflammatory properties of CRP, which 
are mediated by conformational changes from pCRP to bioactive isoforms expressing 
pro-inflammatory neo-epitopes [pCRP* and monomeric C-reactive protein (mCRP)]. 
Here, we investigate the role of CRP isoforms in renal ischemia/reperfusion injury (IRI).
Methods: Rat kidneys in animals with and without intraperitoneally injected pCRP were 
subjected to IRI by the time of pCRP exposure and were subsequently analyzed for 
monocyte infiltration, caspase-3 expression, and tubular damage. Blood urea nitrogen 
(BUN) was analyzed pre-ischemia and post-reperfusion. CRP effects on leukocyte recruit-
ment were investigated via intravital imaging of rat-striated muscle IRI. Localized con-
formational CRP changes were analyzed by immunohistochemistry using conformation 
specific antibodies. 1,6-bis(phosphocholine)-hexane (1,6-bisPC), which stabilizes CRP 
in its native pentameric form was used to validate CRP effects. Leukocyte activation was 
assessed by quantification of reactive oxygen species (ROS) induction by CRP isoforms 
ex vivo and in vitro through electron spin resonance spectroscopy. Signaling pathways 
were analyzed by disrupting lipid rafts with nystatin and subsequent ROS detection. In 
order to confirm the translational relevance of our findings, biopsies of microsurgical 
human free tissue transfers before and after IRI were examined by immunofluorescence 
for CRP deposition and co-localization of CD68+ leukocytes.
results: The application of pCRP aggravates tissue damage in renal IRI. 1,6-bisPC 
reverses these effects via inhibition of the conformational change that leads to exposure of 
pro-inflammatory epitopes in CRP (pCRP* and mCRP). Structurally altered CRP induces 
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leukocyte–endothelial interaction and induces ROS formation in leukocytes, the latter 
can be abrogated by blocking lipid raft-dependent signaling pathways with Nystatin. 
Stabilizing pCRP in its native pentameric state abrogates these pro-inflammatory effects. 
Importantly, these findings are confirmed in human IRI challenged muscle tissue.
conclusion: These results suggest that CRP is a potent modulator of IRI. Stabilizing 
the native pCRP conformation represents a promising anti-inflammatory therapeutic 
strategy by attenuation of leukocyte recruitment and ROS formation, the primary path-
omechanisms of IRI.
Keywords: c-reactive protein, ischemia/reperfusion injury, reactive oxygen species, therapeutic targets, 
conformational change, translational medical research, leukocyte recruitment, rat models
inTrODUcTiOn
Ischemia/reperfusion injury (IRI) is an inflammatory response 
that occurs when tissue is reperfused following a prolonged 
period of ischemia (1). The main responsible pathomechanisms 
of this inflammation are often overshooting leukocyte activation 
(2, 3), complement activation (4), and generation of reactive 
oxygen species (ROS) (5–7) that lead to the release of pro-
inflammatory cytokines and increased vascular permeability 
and consequently result in tissue damage. Renal IRI is inevitable 
in many clinical situations such as renal transplantation, vascu-
lar surgery (8), acute ischemic renal injury, and delayed graft 
function (9). Due to the relatively limited understanding of the 
pathophysiology, there is to date no specific treatment of this 
devastating clinical condition. The current research, therefore, 
addresses the major medical need to identify new therapeutic 
approaches to IRI.
Recently, we have been able to show that C-reactive protein 
(CRP), an acute phase reactant that is elevated after tissue 
injury, undergoes conformational changes from its circulating 
native pentameric isoform (pCRP) to a bioactive conforma-
tion (pCRP*). pCRP* binds complement C1q and activates 
the classical complement pathway. It then further dissociates 
into monomeric CRP subunits [monomeric C-reactive protein 
(mCRP)], which exert further pro-inflammatory actions before 
they are cleared by phagocytes (10–14). These conformational 
changes are mediated by bioactive lipids (15) on activated or 
damaged cells or platelets (10, 16). Conformation-specific anti-
bodies can detect a neo-epitope (that is, residues 199–206 of 
CRP become accessible), which is present on both pCRP* and 
mCRP, but not on pCRP (10, 17). This neo-epitope mediates 
most of the pro-inflammatory CRP effects (12, 18). pCRP* is 
the major pro-inflammatory isoform in  vivo, but exists only 
on biological surfaces and thus cannot be purified for in vitro 
use. Therefore, mCRP is commonly used as surrogate to study 
Abbreviations: CRP, C-reactive protein; mCRP, monomeric C-reactive protein; 
pCRP, pentameric C-reactive protein; pCRP*, neo-epitope expressing CRP; IRI, 
ischemia/reperfusion injury; 1,6-bisPC, 1,6-bis(phosphocholine)-hexane; PBMC, 
peripheral blood mononuclear cells; PMN, polymorphonuclear cells; D-PBS, 
Dulbecco’s physiological phosphate-buffered saline; NADPH, reduced nicotina-
mide adenine dinucleotide phosphate.
pro-inflammatory pCRP* effects in  vitro as it presents the 
same bioactive epitopes. mCRP leads to increased monocyte 
activation, adhesion, and transmigration, as well as formation 
of ROS (10) and activation of the complement system (12), 
which represent major pathophysiological factors contribut-
ing to tissue injury in IRI. Thus, we hypothesized that the 
conformational change of pCRP and the consecutive aggrava-
tion of inflammation might be a pathophysiological mechanism 
by which inflammation is regulated and localized in IRI and 
thus represents a therapeutic target to reduce tissue damage 
in IRI.
MaTerials anD MeThODs
reagents
Human pCRP was purchased from Calbiochem (Nottingham, 
UK; purified from human ascites) and was dialyzed against 
Dulbecco’s phosphate buffered saline with Ca2+/Mg2+ (D-PBS) 
(ThermoFisher Scientific) to prevent potential contaminations 
and tested as described before (11, 12). 1,6-bisPC was synthesized 
by Syngene International, Bangalore, India. Lipopolysaccharide 
(LPS) from E. coli serotype O127:B8 for intravital microscopy 
was obtained from Sigma-Aldrich. As described previously, 
we utilized and prepared mCRP (1  mg/ml) in soluble, citra-
conylated form (19). Conformation-specific CRP antibodies 
clone 8D8 and 9C9 were kindly provided by Dr. Larry Potempa 
(College of Pharmacy, Roosevelt University, Schaumburg, IL, 
USA) (20).
animals
Male Wistar rats were purchased from Charles River Research 
Models and Services (Sulzfeld, Germany). For the renal IRI-
model, all rats were 6 weeks old and body weight was between 
180 and 220 g. Male Wistar rats for intravital microscopy were 
selected and handled as previously described (11). Animals 
were housed in light controlled rooms (12 h light/dark cycle) 
and allowed access to food and water ad libitum. This study was 
carried out in accordance with the recommendations of the 
animal ethic committee of the University of Freiburg Medical 
Center, Germany. The protocol was approved by the animal 
ethic committee of the University of Freiburg Medical Center, 
Germany.
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human studies
For immunohistology of human ischemia/reperfusion-injured 
tissue, biopsies of 15 patients receiving free muscle flap recon-
struction of posttraumatic soft tissue defects of the lower 
extremity were taken between September 2008 and March 2010. 
Informed consent was obtained from each patient. The study was 
approved by the ethic committee of the University of Freiburg 
Medical Center (Application number: 67/08) and conducted in 
accordance with the declaration of Helsinki.
renal ischemia/reperfusion-injury Model
Prior to surgery, 30 Wistar rats were randomly allocated to 
one of five designated groups; (1) sham-operated controls 
receiving flank incisions without renal clamping. Animals 
received i.p. vehicle D-PBS solution treatment; (2) IRI-treated 
rats were subjected to the surgical procedure described 
hereafter. IRI rats received i.p. 500 µl D-PBS application; (3) 
IRI +  pCRP-treated rats: the same surgical procedure as in 
group (2) was performed. Animals received i.p. pCRP applica-
tion in a 25 µg/ml serum concentration instead of D-PBS; (4) 
IRI + pCRP +  1,6-bisPC-treated group: as in group (3) rats 
received i.p. pCRP appli cation in a 25 µg/ml serum concentra-
tion. pCRP was incubated with 1,6-bisPC (1:100 molar ratio) 
before administration; (5) IRI  +  1,6-bisPC-treated group: 
the same surgical procedure as in group (2) was performed. 
Animals received i.p. 1,6-bisPC application only (n =  6 per 
group).
experimental Protocol of renal iri
The surgical procedure was a modification of the renal IRI-model 
described by Delbridge et al. (21). A bilateral ischemic AKI modi-
fication was considered more relevant to human pathological 
conditions (22). In brief, Wistar rats were anesthetized with 1.5–2 
vol% isoflurane (Abbott, Wiesbaden, Germany) via silicone mask 
and received subcutaneous buprenorphine (0.05  mg/kg body 
weight) (23) for pain relief. Buprenorphine is a convenient option 
for analgesics in IRI-models since it is long-acting with a high 
therapeutic index and metabolized in the liver (24). Adequate 
depth of anesthesia to commence following surgery was achieved 
by loss of reflexes to toe pinch test and distinct slowing of respira-
tory rate. An eye lubricating ointment (Bepanthen, Bayer Vital 
GmbH, Leverkusen, Germany) was used to avoid postoperative 
blinding of the rat. Animals were placed in lateral recumbency 
on a heated surgical table to maintain core body temperature at 
37°C (anal probe-controlled) to avoid effects of the body tem-
perature on the severity of IRI (21, 22). Both renal pedicles were 
exposed via two paravertebral flank incisions and clamped 
with nontraumatic micro vessel clips for 45  min followed by 
24  h reperfusion. A gradual change in color from light red to 
dark purple served as a surrogate parameter for a successfully 
induced ischemia of the kidney. The kidneys were embedded 
in saline solution soaked gazes during the period of exposure. 
Simultaneously, weight-adapted volume of group-corresponding 
solution was administered intraperitoneally. Serum volume was 
estimated as described before (11) as a function of the body weight 
(25). A second bolus was injected i.p. after 12 h of reperfusion 
and constant serum levels of pCRP were verified by immunologic 
turbidity measurements. Immediately after surgery, subcutane-
ous saline supplementation was given to avoid dehydration of 
the rats. All microsurgical procedures were conducted using a 
stereo microscope (Stemi 2000, Carl Zeiss).
Measurement of Blood Urea nitrogen 
(BUn)
Renal function was assessed by BUN concentration (26, 27). 
Blood samples were obtained via lateral tail vein sampling in 
micro tubes with clotting activator (Micro tube 1.3 ml Z, Clotting 
Activator/Serum, Sarstedt, Nümbrecht, Germany). Preparation 
of clotted blood samples was conducted using a precooled tab-
letop centrifuge (Eppendorf centrifuge 5427R, Eppendorf AG, 
Hamburg, Germany). To receive designated serum, probes were 
centrifugated at 2,000 ×  g for 10  min at 5°C. Measurement of 
BUN concentration was performed using cobas 8000 modular 
analyzer (cobas 8000 modular analyzer series, Roche, Basel) 
by the central laboratories of the University Medical Center, 
Freiburg. To avoid invalidation, samples that showed macro-
scopic levels of hemolysis were excluded.
immunostaining and histomorphological 
evaluation
Immunohistochemistry and histomorphological evaluation 
of the renal tissue was performed on formalin-fixed paraffin-
embedded renal tissue sections (5  µm thick serial sections). 
Previously, both kidneys were flushed till bloodlessness with 
D-PBS followed by 4% formalin for fixation. Kidneys were then 
excised and examined in blinded fashion by two researchers 
using a Zeiss microscope (Carl Zeiss Microscopy Axio Imager.
M2, Germany). Staining was performed as described previously 
(17, 28, 29) with minor modifications. Paraffin-embedded sec-
tions were de-paraffinized in xylol, rehydrated, and boiled for 
20 min in concentrated citric acid (pH 6.0). Antigen unmasking 
for anti-monocyte detection was done by application of pepsin 
solution (Digest-All™ 3, life technologies) at room temperature 
for 20 min (30). Histomorphological changes were evaluated on 
Periodic acid–Schiff stained sections by quantitative measure-
ment of tubulointerstitial injury, which was assessed by loss of 
tubular brush border and cast formation following an established 
protocol (31, 32). In brief, the morphological assessment was 
scaled in five steps: with not present (0), mild (1), moderate 
(2), severe (3) to very severe (4). Transmigrated leukocytes 
were detected by anti-monocyte/macrophage antibody clone 
ED-1 (Millipore, Billerica, MA, USA) in a 1:100 dilution and 
renal inflammation was evaluated by counting ED-1+ cells 
in 20 randomized areas of interest of the renal cortex at ×200 
magnification. The number of apoptotic cells was evaluated 
using anti-caspase-3 antibody (Novus Biologicals, Abingdon, 
UK) in a 1:1,000 dilution (33). Sections were counterstained with 
Mayer’s hematoxylin. Negative immunocontrols were issued by 
sections to which primary antibodies had not been added. Each 
parameter was determined on at least five different animals per 
group. As a proof of concept, detection of human CRP on the 
renal tissue sections was performed using anti-pCRP*/mCRP 
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antibody 9C9 (1:100 dilution). The immunostaining for CRP 
conformations in cremaster muscle was conducted following the 
surgical procedure described below. The cremaster muscle was 
excised, snap-frozen, and conserved in tissue freezing medium 
(Leica Microsystems, Nussloch, Germany). Tissue samples 
were cut serially in horizontal direction into 6 µm sections. For 
conformation specific detection of pCRP, we utilized antibody 
clone 8D8 and antibody clone 9C9 was used for the detection 
of conformationally altered CRP (pCRP*/mCRP) (1:100 dilu-
tion) (34). Immunostaining proceeded as described in earlier 
work (10).
intravital Microscopy studies  
of rat cremaster Muscle
As previously described (11, 12) and published in a detailed 
protocol (35), leukocyte–endothelial interaction was observed 
in the microcirculation of the cremaster muscle in male 
Wistar rats (weighing 120–180 g) using intravital microscopy. 
Briefly, the rats were anesthetized with 1.5–2 vol% isoflurane 
and volume controlled ventilated via tracheotomy (Servo 
Ventilator 900C, Maquet, Rastatt, Germany; settings: frequency 
35–45 breaths/min, tidal volume 4.5–5 ml, FiO2 0.35–0.5). Vital 
parameters (heart rate, mean arterial pressure, blood gases) were 
monitored through a cannulated carotid artery. Intravenous 
injection of rhodamine 6G (0.4  mg/kg body weight, Sigma-
Aldrich) (36) via an established jugular vein port stained the 
circulating leukocytes and enabled for intravital tracking. After 
externalization of the cremaster muscle and visualization of the 
cremasteric microcirculation, leukocyte rolling and adherence 
was assessed. Leukocyte rolling was defined as significantly 
slower moving leukocytes compared to erythrocytes within the 
same vessel. Adherent leukocytes remained stationary for 20 s 
or more.
Western Blot analysis
Native Western blot analysis was conducted for CRP detection 
in the cremaster muscle as described previously (11). Briefly, 
muscle tissue was excised and homogenized on ice using a high-
power disperser (Ultra-Turrax® IKA, Staufen, Germany). The 
purification of the cell lysates was determined by a BCA protein 
assay kit (Sigma-Aldrich) and portioned. After the separation 
by SDS gel electrophoresis and the transfer to Hybond ECL 
nitrocellulose membranes (GE Healthcare, Munich, Germany), 
samples were probed with anti-pCRP*/mCRP antibody for 1 h 
at RT. To ensure equilibration, we used monoclonal antibodies 
against GAPDH (abcam, Cambridge, UK). An anti-mouse horse-
radish peroxidase-conjugated secondary antibody (Dianova, 
Hamburg, Germany) was utilized for detection using enhanced 
chemiluminescence (ECL, GE Healthcare) and conserved on 
Hyperfilm ECL (GE Healthcare). Cell lysis and Western blotting 
buffer were used as described earlier (11).
electron spin resonance (esr) 
spectroscopy for the study of  
leukocyte-Derived rOs
For ex vivo experimental procedures, we utilized ESR 
spectroscopy to identify and quantify ROS formation in rat 
leukocytes. CMH (1 mM, 1-hydroxy-3-methoxycarbonyl-2,2,5,5- 
tetramethylpyr rolidine, Noxygen, Elzach, Germany) was 
adopted as a spin label suitable for biological utilization as 
described before (37). After the intravital experimental pro-
cedure, whole blood samples were collected in EDTA tubes 
by cannulation of the abdominal aorta and mononuclear cells 
[peripheral blood mononuclear cells (PBMC) and polymor-
phonuclear cells (PMN)] were isolated by Ficoll density gradi-
ent (Bicoll Separating Solution, Biochrom, Berlin, Germany; 
density 1.077  kg/m3) centrifugation as described before 
(11). MiniScope MS 200 ESR Spectrometer (Magnettech, 
Berlin, Germany) was used for measurements with following 
instrument settings: center field, 3,340G; sweep wide, 60G; 
sweep time, 5 ms over 10 scans; modulation amplitude, 2.4G; 
microwave power, 10 mW. Positive controls were conducted by 
cremasteric superfusion with LPS in concentration 1  µg/ml. 
For the pCRP/mCRP groups, 25  µg/ml pCRP or mCRP was 
administrated intravenously. Blood samples were taken 60 min 
after the treatment.
For in  vitro experiments, whole blood samples were col-
lected from rats and healthy human donors and PBMC and 
PMN were isolated as described above. The cell suspensions 
were then incubated at 37°C for 30 min with PBS only (con-
trol), LPS (50 µg/ml), pCRP (10 µg/ml), and mCRP (10 µg/ml), 
respectively.
statistical analysis
Statistical analysis was performed using GraphPad Prism 
v7.0 software (GraphPad Software, San Diego, CA, USA). For 
comparison of two groups, a two-tailed t-test was employed. 
Experimental data were compared using one-way ANOVA 
to compare effects of different treatments, if more than two 
groups were compared. In case of significance, Turkey’s test 
was performed for pairwise comparison. To analyze treatment 
effects over time, we performed a two-way repeated measures 
(mixed model) ANOVA with the fixed factors “time,” “treat-
ment,” and the corresponding interaction term. In case of a 
non-significant interaction and significant treatment effect, 
pairwise Bonferroni adjusted comparisons were performed at 
each time point. Significant results for both two-way repeated 
measures (mixed model) ANOVA and Bonferroni post  hoc 
tests are presented. A p-value <0.05 statistical significance 
level was accepted. All data are expressed as scatter plot with 
mean ± SEM.
resUlTs
crP increases Tissue Damage  
in renal iri
Rat renal IRI was quantified by determination of BUN, immu-
nohistological staining for caspase-3 and monocytes as well 
as evaluation of morphological changes after reperfusion. All 
experimental readouts consistently demonstrate that intraperi-
toneal (i.p.) injection of pCRP potentiates renal IRI leading to 
elevated BUN, increased caspase-3 expression, and aggravated 
IRI-specific alterations in tissue morphology. A significant 
FigUre 1 | Continued
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increase in the number of infiltrated monocytes could be detected 
(Figures 1A–E). Immunohistological staining with anti-pCRP*/
mCRP-antibody 9C9 demonstrates that the injected pCRP is 
not deposited in healthy renal tissue, however, accumulates in 
IRI-damaged tubules in its conformationally altered isoforms 
(Figure 1D).
FigUre 1 | Continued
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FigUre 1 | C-reactive protein (CRP) aggravates renal ischemia/reperfusion injury (IRI) in rats. (a) Immunohistochemical detection of CD68+ cells in the renal 
cortex and quantification of the results. Antibody binding was detected with the HistoGreen substrate kit. CD68+ cells were quantified in randomly chosen  
areas of the renal cortex at ×200 magnification. Given are mean cell counts/area per animal. *p < 0.05 for IRI + pentameric C-reactive protein (pCRP) vs. IRI, 
IRI + pCRP + 1,6-bisPC, and IRI + 1,6-bisPC. Values are mean ± SEM; n = 6. The number of CD68+ cells transmigrating in the I/R-injured tissue is significantly 
increased under pCRP application; stabilization of pCRP with 1,6-bisPC abrogates this effect. (B) Localization and quantification of caspase-3 protein in the 
tubular epithelium. Anti-caspase-3 antibody and HistoGreen staining of apoptotic cells in the renal tubules. Given are counts of positive cells. Randomly selected 
areas of the renal cortex were evaluated from each sample. *p < 0.05 for IRI + pCRP vs. IRI/IRI + pCRP + 1,6-bisPC/IRI + 1,6-bisPC. Values are mean ± SEM; 
n = 6. CRP significantly increases the number of apoptotic cells in IRI. This is inhibited by addition of 1,6-bisPC. (c) Histomorphological evaluation of renal 
tissue after IRI using Periodic acid–Schiff (PAS) staining. A minimum of ten fields per slide was examined at ×200 magnification. Shown are mean values per 
animal for the severity of proximal tubule damage. *p < 0.05 for IRI + pentameric C-reactive protein (pCRP) vs. IRI/IRI + pCRP + 1,6-bisPC/IRI + 1,6-bisPC.  
Not significant for IRI vs. IRI + pCRP + 1,6-bisPC and IRI vs. IRI + 1,6-bisPC. (D) Immunohistochemical detection of CRP neo-epitopes with anti-pCRP*/ 
monomeric C-reactive protein (mCRP) antibody 9C9 and HistoGreen after IRI and i.p. application of pCRP ± 1,6-bisPC compared with IRI without pCRP 
application and sham-operated kidneys with pCRP application. After i.p. application of pCRP, conformationally altered CRP is deposited in renal tubules. This is 
not seen when pCRP is pre-stabilized with 1,6-bisPC. (e) Analysis of blood urea nitrogen. Blood samples were taken before ischemia/surgery and after the 24 h 
reperfusion period or 24 h after surgery, respectively. Renal IRI induces a significant increase in BUN, a functional hallmark of renal function in acute kidney injury. 
CRP-dissociation aggravates the functional tissue damage, 1,6-bisPC prevents pro-inflammatory alterations of CRP and partially preserves kidney function. 
*p < 0.05 for IRI + pCRP vs. IRI/IRI + pCRP + 1,6-bisPC/IRI + 1,6-bisPC; *p < 0.05 for all groups pre-ischemia vs. postischemia. (F) Flow chart representing 
the experimental protocol of the renal IRI model.
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crP aggravates leukocyte  
recruitment in iri, but Does not show 
intrinsic Pro-inflammatory Potential in 
sham-Operated animals
In a model of IRI, leukocyte–endothelial interaction in the 
microcirculation of the rat cremaster muscle was observed via 
intravital microscopy.
Moderate inflammatory response was induced by ischemic 
occlusion of the cremaster muscle for 30  min, resulting in an 
increase in leukocyte rolling that reaches statistical significance 
after 60 min and in leukocyte adhesion by 120 min. pCRP infu-
sion has no impact on leukocyte recruitment in the resting muscle 
tissue. However, tissue alteration through IRI results in a marked 
aggravation of the IRI-induced inflammatory response through 
application of pCRP. Thus, the number of rolling leukocytes in 
IRI significantly increases after 60 min and more than doubles to 
the end of the imaging period (Figure 2A). Likewise, leukocyte 
adhesion increases in IRI in the presence of pCRP; however, 
effects are timely delayed compared to rolling leukocytes. Values 
do not reach statistical significance compared to the control until 
120 min after infusion of pCRP (Figures 2B,G).
in iri of striated Muscle Tissue, 
conformationally altered crP is 
Deposited in the interstitial space
Rat cremaster muscle samples were examined for deposition of 
CRP by immunohistochemistry after intravital imaging using 
con formation specific antibodies. Staining reveals that the infused 
native pCRP can only weakly be detected in the interstitial space of 
healthy tissue by anti-pCRP 8D8 antibodies (Figure 2C). This is in 
contrast to the IRI-mediated inflamed muscle tissue, where total 
amounts of CRP deposition increases (Figure 2D). Here, CRP is 
in large parts detectable by anti-pCRP*/mCRP 9C9 anti bodies 
and thus deposited in its conformationally altered isoforms.
Blocking the crP conformational change 
abrogates Pro-inflammatory effects
The small molecule inhibitor 1,6-bisPC is able to stabilize 
pCRP in a decameric confirmation, thereby inhibiting the 
pro-inflammatory conformational change (pCRP*/mCRP) 
(11). Here, we show that the decameric stabilization pre-
vents deposition of CRP in IRI-altered tubules of the kidney 
(Figure 1D). Conformation-specific staining for CRP as well as 
native Western blotting of the cremasteric tissue (Figures 2C–F) 
reveals that 1,6-bisPC prevents the dissociation of pCRP in 
IRI, thereby impending the deposition of pCRP*/mCRP in 
the interstitial space. This in turn masks the pro-inflammatory 
contribution of CRP to the inflammatory reaction in renal IRI 
as well as in IRI of striated muscle tissue. Significant decreases 
in caspase-3 expression, monocyte infiltration, and tubular 
damage clearly demonstrate the protective effect of 1,6-bisPC 
in the CRP-induced tissue damage in renal IRI (Figures 1A–C). 
This is also reflected in the significant decrease in BUN under 
1,6-bisPC compared to the elevated concentrations in IRI 
under CRP alone (Figure 1E). 1,6-bisPC does not only soften 
the CRP driven inflammatory response in IRI detected after 
a 24  h reperfusion period but also modulates the immediate 
inflammatory reaction after ischemia. This is reflected in a 
mitigated leukocyte–endothelial interaction in the microcircu-
lation of the IRI-challenged cremasteric tissue after pretreat-
ment of pCRP with 1,6-bisPC, showing significant decreases in 
leukocyte rolling and adhesion after 120 min. 1,6-bisPC alone, 
however, shows neither pro- nor anti-inflammatory potential 
(Figures 2A,B).
exposition of Pro-inflammatory  
neo-epitopes in inflamed Tissue can  
Be Mimicked by Pre-Dissociated crP
In order to analyze the pro-inflammatory potential of CRP 
when neo-epitopes are exposed, we used pre-dissociated 
mCRP in rat intravital microscopy. Superfusion of the cremas-
ter muscle with (LPS) (1  µg/ml) served as positive control. 
mCRP but not pCRP infusion leads to a rapid increase of 
leukocyte rolling in the cremasteric microcirculation with 
significant differences after 20 min compared to the control 
and to the pCRP group (Figures 3A,C). This is in line with the 
increase in the number of adherent leukocytes under mCRP, 
though values do not reach statistical significance before 
50  min (Figures  3B,D). Subsequent conformation-specific 
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FigUre 2 | Continued
immunohistochemical staining of the cremaster muscle 
reveals that the infused mCRP is extensively deposited in and 
around cremasteric vessels. pCRP can only be detected in 
trace amounts in the cremasteric tissue after pCRP infusion 
(Figures 3E,F).
mcrP induces respiratory Burst in  
rat and human leukocytes Which  
is Mediated by lipid rafts in PBMc
Generation of ROS was assessed ex vivo in rat PBMC 
(Figure  4A) and PMN (Figure  4B) via ESR spectroscopy. 
FigUre 2 | C-reactive protein (CRP)-induced aggravation of ischemia/reperfusion injury (IRI) is controlled by a localized conformational change regulating leukocyte 
recruitment. (a,B) Intravital microscopy of rat cremasteric postcapillary venules to determine leukocyte–endothelial interaction in IRI ± i.v. injection of pentameric 
C-reactive protein (pCRP) (25 µg/ml). Leukocytes were labeled with Rhodamine 6G. Counts at 0 min was set to 100%. Values are mean ± SEM of 10–14 observed 
venules in 6 rats. #p < 0.05. i.v. application of pCRP aggravates IRI and significantly increases leukocyte rolling (a) and adhesion (B). 1,6-bisPC masks the 
pro-inflammatory potential of CRP in IRI and induces a significant decrease in leukocyte rolling (a) and adhesion (B) compared to the IRI + pCRP group. 1,6-bisPC 
alone has neither pro- nor anti-inflammatory potential. (c,D) Immunohistochemical staining of the cremaster muscle with DAB after IRI ± i.v. application of pCRP. 
Clone 8D8 (c) was used to detect pCRP and clone 9C9 (D) was used to detect conformationally altered CRP. Representative results are shown (n = 6 for each 
sample). After i.v. application, pCRP can be detected in the cremasteric tissue (arrow). Staining gets less pronounced in IRI. Neo-epitope expressing CRP is  
strongly detectable after pCRP injection in IRI (arrow), though trace amounts are detected in healthy tissue. IRI induces an alteration of the CRP conformation  
and a deposition in the inflamed tissue. (e) Immunohistochemical staining of the cremaster muscle with DAB after IRI and i.v. application of pCRP ± 1,6-bisPC. 
Stabilization of pCRP by 1,6-bisPC abrogates the formation and deposition of conformationally altered CRP. (F) Western blot analysis of native PAGE (1/20 SDS)  
of I/R-injured rat cremaster muscle tissue stained for mCRP with antibody clone 9C9 and 8D8. In the I/R-injured muscle tissue, altered CRP accumulates after the 
dissociation of pCRP. 1,6-bisPC stabilizes pCRP in its native conformation and, therefore, altered CRP is not detectable in 1,6-bisPC-treated rats. (g) Flow chart  
of the intravital experimental protocol.
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FigUre 3 | Continued
FigUre 3 | Monomeric C-reactive protein (mCRP) is the pro-inflammatory tissue-appealing isoform of C-reactive protein (CRP). (a,B) Leukocyte–endothelial 
interaction under i.v. injection of either mCRP or pentameric C-reactive protein (pCRP) (25 µg/ml) quantified by intravital microscopy. Superfusion of the cremaster 
muscle with lipopolysaccharide (LPS) (1 µg/ml) served as positive control. Counts at 0 min was set to 100%. Values are mean ± SEM of 10–14 observed 
postcapillary venules in six rats. #p < 0.05 compared to the control; *p < 0.05 compared to the pCRP group. mCRP significantly increases leukocyte rolling (a) and 
leads to a rapid increase of leukocyte adhesion (B) during the course of the experimental protocol whereas pCRP shows no significant effect. Images shown under 
(c,D) are typical venules of the four groups after 20 and 50 min. (e,F) Immunohistochemical staining of the cremaster muscle with DAB after i.v. application of pCRP 
(25 µg/ml) and mCRP (25 µg/ml). Clone 8D8 was used to detect pCRP (e) and clone 9C9 was used to detect neo-epitope expressing CRP (pCRP*/mCRP) (F). 
Representative results are shown (n = 6 for each sample). Trace amounts of pCRP can be detected in the cremasteric tissue in the pCRP group. mCRP application 
results in a pronounced positive staining for mCRP particularly around cremasteric vessels (arrow).
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In both leukocyte subsets, intravenous treatment with mCRP 
significantly increases ROS formation. In contrast, the infu-
sion of pCRP showed no such effect. This is in line with the 
in vitro stimulation of previously isolated PBMC (Figure 4C) 
and PMN (Figure 4D) where mCRP also significantly induces 
ROS formation. These results can be reproduced for human 
isolated leukocytes (Figures  4E,F). Figure  4G shows repre-
sentative ESR spectra. To investigate the signi ficance of lipid 
rafts in the CRP-mediated respiratory burst, isolated PBMC 
and PMN were treated with Nystatin prior to incubation with 
CRP. ESR spectroscopy reveals that disruption of lipid rafts on 
PBMC masks the pro-inflammatory potential of mCRP result-
ing in a significant decrease in ROS formation (Figure 4I). On 
PMN, however, treatment with Nystatin failed to eliminate the 
pro-inflammatory potential of mCRP (Figure  4J) indicating 
alternative signaling pathways.
crP is Deposited in the iri of human 
striated Muscle Tissue and co-localizes 
With cD68+ leukocytes
Immunofluorescence with conformation specific detection of CRP 
and CD68+ cells in striated human muscle tissue shortly before 
(pre-ischemia) and after free tissue transfer (post-reperfusion) 
revealed extensive deposition of neo-epitope expressing CRP in 
the IRI-challenged tissue (Figure 5A). pCRP is detected in the 
reperfused muscle; however, deposition shows no significant 
increase when compared to pre-ischemic values. Elevated num-
bers of CD68+ leukocytes co-localize with neo-epitope expressing 
CRP in the inflamed tissue (Figure 5B).
DiscUssiOn
Here, we identify and characterize the role of CRP in the 
pathological cascade of IRI by two distinct in vivo models of IRI, 
renal IRI, and IRI of striated muscle tissue. We further analyze 
the underlying mechanisms of CRP mediated tissue damage. 
Based on our findings, inflammatory tissue impairment in 
IRI can potentially be targeted by the prevention of molecular 
changes in CRP structure. This is supported by the follow-
ing findings: (1) CRP aggravates renal IRI in a rat model and 
aggravates ischemia induced renal damage. (2) CRP undergoes 
a conformational change in renal IRI leading to exposure of 
pro-inflammatory epitopes (pCRP*/mCRP). (3) mCRP induces 
significant leukocyte activation in the microcirculation of the rat 
cremaster muscle. (4) Accumulated CRP in IRI consists mostly 
of conformationally altered isoforms. (5) The pro-inflammatory 
potential of CRP in renal IRI and IRI of striated muscle tissue can 
be blocked by preventing the conformational change of pCRP. 
(6) mCRP, but not pCRP, induces ROS generation in vivo and 
ex vivo. (7) mCRP-mediated ROS formation in PBMC is medi-
ated by lipid rafts. (8) In human IRI of striated muscle tissue, 
neo-epitope expressing CRP accumulates and co-localizes with 
inflammatory cells, suggesting a transferability of our results into 
the in vivo situation in humans.
There is a growing body of evidence suggesting a causal role 
for CRP in IRI. Padilla and coworkers were able to show that 
CRP is an activator of complement in a rat model of intestinal 
IRI (38). Another report revealed that CRP exacerbates renal IRI 
in transgenic human CRP mice compared to a wild-type control 
(39). Only recently, the same group showed in their mouse 
model that myeloid-derived suppressor cells might participate 
in the CRP-driven inflammation in renal IRI (40). Our work 
provides the underlying mechanism by which CRP contributes 
to IRI. We are able to show that pCRP does not exert any pro-
inflammatory effects, which is in line with previous findings 
(41–43). Moreover, we can show that a paramount requirement 
for the aggravation of inflammation by CRP is the expression of 
the pro-inflammatory neo-epitope, thus defining the molecular 
basis for the effects observed in the aforementioned publica-
tions. A rat model was used, as even though rats have abundant 
CRP (300–600 µg/ml in normal healthy pathogen-free rats), it 
does not activate rat complement. This is in contrast to human 
CRP that, similar to the in vivo situation in humans, activates rat 
complement and thus makes the rat the ideal animal model for 
CRP research (44).
We have previously shown that the conformational change 
of circulating pCRP is a localized process limited to the area of 
inflammation (11) and is mediated by activated cell mem branes 
carrying bioactive lipids, such as lysophosphatidylcholine 
(10, 15). In our recent work, we identify an initial structural 
change in the pentameric protein (pCRP*) after binding 
to activated monocytes that leads to the expression of pro-
inflammatory neo-epitopes resembling those of mCRP (12). 
The pathophysiological cascade from pCRP binding to activated 
membranes, consecutive generation of pCRP* and finally 
mCRP formation has proven its pro-inflammatory potential 
in  vitro (12) and in an in  vivo model of acute inflammation 
(11). Here, we demonstrate the significance of structural 
alterations in CRP for the first time in clinically highly 
relevant renal IRI. Inhibiting the conformational change of 
pCRP with a compound that stabilizes pCRP in a decameric 
conformation, first described by Pepys et al. (45) abrogates all 
CRP effects. We have recently shown that in this decameric 
conformation, CRP is not able to undergo its conformational 
change with exposure of pro-inflammatory epitopes (11, 46). 
FigUre 4 | Continued
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In the IRI models that we investigated herein, 1,6-bisPC 
blunts the pro-inflammatory effects of CRP that promoted an 
aggravated inflammatory reaction beforehand. 1,6-bisPC itself, 
however, shows no intrinsic anti-inflammatory potential. We 
thereby confirm the conformational change as “conditio sine qua 
non” for the pro-inflammatory properties and provide prove 
of the feasibility of therapeutically locking pCRP in its native 
isoform in order to attenuate IRI-induced tissue damage.
FigUre 4 | Monomeric C-reactive protein (mCRP) increases reactive oxygen species (ROS) formation in rat leukocytes. This is reproducible for human leukocytes. 
Nystatin disrupts the pro-inflammatory signaling of mCRP in rat peripheral blood mononuclear cells (PBMC). (a,B) Ex vivo electron spin resonance (ESR) detection 
using CMH (25 µg/ml) as spin label in rat PBMC and polymorphonuclear cells (PMN) after in vivo treatment with p-/mCRP (25 µg/ml). Values are mean ± SEM of 
four different rats. #p < 0.05 compared to the control group. *p < 0.05 compared to the pentameric C-reactive protein (pCRP) group. mCRP induces a significant 
stimulation of ROS in PBMC (a) as well as in PMN (B). Cremasteric superfusion with lipopolysaccharide (LPS) (1 µg/ml) served as control. (c,D) In vitro ESR 
detection in isolated rat PBMC and PMN after incubation with p-/mCRP (10 µg/ml). LPS (50 µg/ml) served as positive control. Values are mean ± SEM of eight 
different rats. #p < 0.05 compared to the control group. *p < 0.05 compared to the pCRP group. mCRP induces a significant stimulation of ROS in PBMC as well as 
in PMN. (e,F) In vitro ESR detection in isolated human and rat PBMC/PMN after incubation with p-/mCRP (10 µg/ml). LPS (50 µg/ml) served as positive control. 
Values are mean ± SEM of at least three different rats/human donors. #p < 0.05 compared to the control group. *p < 0.05 for pCRP vs. mCRP. ROS stimulation by 
mCRP in rat leukocytes can be reproduced in human leukocytes. (g) Representative spectra of electron spin resonance (ESR) spectroscopy. (h) Schematic drawing 
of a lipid raft. (i,J) In vitro ESR detection using CMH (25 µg/ml) as spin label in isolated rat PBMC (i) and PMN (J) after incubation with p-/mCRP (10 µg/ml) ± prior 
treatment with nystatin (25 µg/ml) intending to disrupt lipid rafts. LPS (50 µg/ml) served as positive control. Values are mean ± SEM of eight different rats. #p < 0.05 
compared to the control group. *p < 0.05 for mCRP vs. mCRP + nystatin. Disruption of lipid rafts by nystatin prior to incubation with mCRP significantly decreases 
ROS generation in PBMC. Signal drop did not reach statistical significance in PMN.
FigUre 5 | Conformationally altered C-reactive protein (CRP) accumulates in inflamed human muscle tissue. (a) Immunofluorescence conformation-specific 
detection of C-reactive protein and CD68+ cells in striated human muscle tissue shortly before (pre-ischemia) and after free tissue transfer (post-reperfusion). 
Conformation-specific antibody clone 8D8, which recognizes exclusively pentameric C-reactive protein (pCRP) and clone 9C9, recognizing neo-epitopes expressed 
by pCRP*/monomeric C-reactive protein (mCRP), were used. Typical results are given. (B) Quantification shows relative values of immunoreactivity for CD68+ cells 
and pCRP and pCRP*/mCRP, respectively. At least three non-overlapping images were evaluated from each sample to determine the corresponding value. 
#p < 0.05 for pre-ischemia vs. ischemia/reperfusion injury (IRI). Values are mean ± SEM; n = 15. IRI leads to a significant increase of p- and especially 
conformationally altered CRP deposition, which co-localizes with CD68+ leukocytes.
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FigUre 6 | Schematic drawing of CRP-driven leukocyte response in ischemia/reperfusion injury (IRI). Circulating pentameric C-reactive protein (pCRP) (yellow) 
binds to activated biomembranes in the microcirculation of inflamed tissue. It is subsequently conformationally altered to bioactive pCRP*, dissociates and forms 
mCRP (red circles). Neo-epitope expressing CRP induces leukocyte–endothelial interaction and activation of the ROS producing NADPH oxidase enzyme complex. 
1,6-bisPC (green–white pill) prevents the CRP-mediated leukocyte activation by stabilizing the native pentameric isoform of CRP.
13
Thiele et al. CRP Aggravates IRI
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 675
The mCRP-induced ROS generation in  vitro is a significant 
finding of our work, which is also confirmed ex vivo. The forma-
tion of oxygen radicals is of causal relevance in various diseases, 
such as atherosclerosis (47), myocardial infarction (48, 49), and 
other inflammatory diseases (50). We investigated the generation 
of ROS ex vivo in leukocytes by ESR spectroscopy following 
in  vivo exposition to p-/mCRP, thereby indicating leukocyte 
activation and oxidative stress. This was further supported by the 
in vitro analysis of CRP-induced radical formation in leukocytes. 
Our findings demonstrate that mCRP induces oxidative stress in 
different leukocyte subsets, which potentially aggravates tissue 
damage in the course of IRI associated inflammation.
Recent literature proposes mCRP–lipid raft interaction as 
an important mechanism in mediating cellular responses to 
mCRP in human cells (Figure 4H) (10, 51). Lipid rafts represent 
dynamic, detergent-resistant plasma membrane microdomains 
that are highly enriched in cholesterol and sphingolipids and 
play critical roles in cellular signaling (52, 53). For the interac-
tion of mCRP with lipid rafts, a direct membrane integration 
of mCRP has been proposed (51). At the same time, the FcγR-I 
can be found in lipid raft microdomains (54) and has previously 
been identified as a potent pro-inflammatory mediator of mCRP 
on human monocytes (11) and potent inductor for ROS forma-
tion (55) via induction of NADPH oxidases (56). Disruption 
of lipid rafts with nystatin abrogates the potential binding 
sites for mCRP in lipid rafts microdomains. This inhibits the 
mCRP-induced respiratory burst in PBMC, however, fails to 
abrogate the pro-inflammatory CRP effects in PMN. This might 
be explained through distinct receptor patches on different leu-
kocyte subsets such as a higher significance of FcγR-IIIa in PMN 
that has shown to mediate mCRP signaling (11). The inhibition 
of mCRP signal transduction by nystatin in PBMC, which does 
not inhibit LPS-induced generation of ROS, furthermore con-
firms the specificity of the mCRP effects, as it rules out potential 
influences of contaminating bacterial products as described by 
other authors (57).
In conclusion, we demonstrate that CRP aggravates IRI via 
various pro-inflammatory mechanisms. Formation of neo-
epitope expressing CRP leads to significant renal damage and 
induces leukocyte–endothelial interaction and generation of 
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ROS. These effects are in part mediated by lipid raft signaling and 
can be therapeutically targeted by blocking pCRP dissociation 
with 1,6-bisPC (Figure 6).
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